<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596905</url>
  </required_header>
  <id_info>
    <org_study_id>SP304202-14</org_study_id>
    <nct_id>NCT03596905</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Plecanatide in Children 6 to &lt;18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)</brief_title>
  <acronym>(IBS-C)</acronym>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Dose Ranging, Parallel-Group Study of the Efficacy and Safety of Plecanatide in Children 6 to &lt;18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study of the efficacy and safety of Plecanatide in children 6 to &lt;18 Years of Age with
      Irritable Bowel Syndrome with Constipation (IBS-C)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy and pharmacokinetic (PK)
      parameters of plecanatide of once daily oral 4 dose levels of plecanatide (0.5, 1.0, 2.0, or
      3.0 mg) for 4 weeks as treatment in children 6 to &lt;18 years of age with IBS-C.

      The study will include a 28-day Screening/Baseline Period, a 4 week treatment period, and a
      2-week post-treatment follow-up period. Patients/caregivers will visit the clinic 4 times
      during the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in weekly SBM frequency over the 4 Week Treatment Period compared to placebo and across treatment groups</measure>
    <time_frame>4 Week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency and severity of abdominal pain/discomfort</measure>
    <time_frame>4 Week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of BMs and CSBMs</measure>
    <time_frame>4 Week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in stool consistency (BSFS or mBSFS-C)</measure>
    <time_frame>4 Week</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Irritable Bowel Syndrome With Constipation</condition>
  <arm_group>
    <arm_group_label>0.5 mg plecanatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg plecanatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to &lt; 18 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg plecanatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to &lt; 18 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.0 mg plecanatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to &lt; 18 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to &lt; 18 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plecanatide</intervention_name>
    <description>Taken orally daily for 4 weeks</description>
    <arm_group_label>0.5 mg plecanatide</arm_group_label>
    <arm_group_label>1.0 mg plecanatide</arm_group_label>
    <arm_group_label>2.0 mg plecanatide</arm_group_label>
    <arm_group_label>3.0 mg plecanatide</arm_group_label>
    <other_name>Trulance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Taken orally daily for 4 weeks</description>
    <arm_group_label>Matching placebo</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

        A patient will be eligible for study participation if he or she meets all of the following
        criteria:

          1. Male or female child aged 6 to &lt; 18;

          2. Meets ROME IV criteria for child/adolescent IBS-C

          3. Patient's parent/guardian/LAR is able to voluntarily provide written, signed, and
             dated consent and patient is able to voluntarily provide assent as per IRB guidance;

          4. Patient and patient's parent/guardian/LAR demonstrates an understanding, ability, and
             willingness to fully comply with study procedures

        EXCLUSION CRITERIA

        A patient will be excluded from the study if he or she meets any of the following criteria:

          1. The patient has a mental age &lt;4 years in the investigator's opinion;

          2. The patient has previously been diagnosed with anorectal malformations, neurological
             deficits, or anatomical anomalies that would constitute a predisposition to
             constipation;

          3. The patient is pregnant or lactating;

          4. The patient's mobility or normal exercise tolerance is compromised in the
             investigator's opinion;

          5. The patient has been screened for or participated in another Synergy study in the
             past;

          6. The patient has a sibling that is currently participating or has participated in
             another Synergy study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Bulawski</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matt Markovich</last_name>
    <phone>908-541-1341</phone>
    <email>Matthew.Markovich@bauschhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Harris</last_name>
    <email>susan.harris@bauschhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Crowley</city>
        <state>Louisiana</state>
        <zip>70526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Synergy Research Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plecanatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

